EGFR and head and neck squamous cell carcinoma: In combination with other tyrosine kinase inhibitors (TKI) several c-MET inhibitors such as GSK1363089, INC280, MGCD516 entered clinical trials for patients with HNSCC as single agent or in combination with EGFR-targeting antibody cetuximab (NCT00725764, NCT02205398, and NCT02219711).